We all know what direction $RADX going following the path of $RYZB and $PNT
Radiopharma Theranostics CEO came from Novartis which produced the 2 blockbuster Pluvicto and Lutathera.
And Lantheus just upped their ownership by buying stock at $11.34 (They are the market leader)
$YMAB
Lantheus the $7 billion radioisotope imaging giant just bought $5 million of the $36 million market cap Radiopharma Theranostics at over double current stock price. They own 12% and are throwing them money to work on their trials in Australia.
+ flush pipeline of Lu-177 therapeutics and imaging agents in the clinic.
$CLRB $PNT $RADX
@FonsieTrader - objectively speaking, this is a grossly undervalued company as compared to it's peers....and the space is HOT! -- $FUSN, $PNT, $CATX, mariana
With a late stage asset (Iomab-B) that had knockout Ph3 results it appears to be more of a valuation stand-off between BP and ATNM. I think a well negotiated CVR gets this over the finish line in '24.
I'll invite @resume777 , @Karmic to add their take on this as well
$ATNM
I presume many like me who owned both $ATNM and $FUSN and who made a killing on $FUSN are now doubling down into $ATNM.
Also a bunch of people who knew little to nothing of RadioPharma are now fully awake after $PNT, $RYZB and now $FUSN were bought out for impressive premiums.
At 200 million of market cap acquiring a sizeable position will need a lot of small shareholders to sell to the big fish. This company is extraordinarily cheap by any metric.
$CATX seems that PB is best radioisotope - this was also confirmed when $PNT (just $LLY before BO was announced signed a strategic supply deal for PB… so $catx is leading with this tech… while most others are using Actinium
$LNTH $PNT Might not be the last word on PNT 2002.
"Importantly, participants in the control arm could “cross over” to receive PNT2002 if their disease progressed. Some 84% of those who experienced progression ended up doing so, potentially confounding the study’s survival results. At the time of the analysis, survival results favored the control arm, but the picture could change as more data are accrued as the study continues. Point said additional results are expected next year.
A similar pattern happened in Novartis’ study of Pluvicto, which showed treatment led to a median progression-free survival of 12 months, but no survival benefit.
For Lilly, the SPLASH results may be beside the point.... Their interest in Point had equally as much to do with the company’s manufacturing and research capabilities.
“Our interest in Point is a lot around the platform,” said Lilly’s CMO. “I think the time is right to get into therapeutic radiopharmaceuticals.”
$LNTH $PNT Anyone have a good read on the PNT 2002 trial? Hit the primary endpoint, but came up short on the secondary--overall survival. In the press result, it said data was was not mature, only 49% of patients available. Any thoughts? Will OS improve? And if it doesn't, is the drug a dud? Has one hell of a TAM, if it is successful, in the billions.
$PNT $RYZB very hot space surprise surprise as another one for solids gets absorbed. Not too many go-it alones left in the 'race'! Big $PSTV Plus Point! $FUSN or $NBTX likely next ones to go. Horses for courses.
